ACE2, ACE, DPPIV, PREP and CAT L enzymatic activities in COVID-19: imbalance of ACE2/ACE ratio and potential RAAS dysregulation in severe cases

被引:3
作者
Neves, Raquel Leao [1 ]
Branquinho, Jessica [1 ]
Arata, Julia Galanakis [1 ]
Bittencourt, Clarissa Azevedo [1 ]
Gomes, Caio Perez [1 ]
Riguetti, Michelle [2 ]
da Mata, Gustavo Ferreira [2 ]
Fernandes, Danilo Euclides [2 ]
Icimoto, Marcelo Yudi [3 ]
Kirsztajn, Gianna Mastroianni [2 ]
Pesquero, Joao Bosco [1 ]
机构
[1] Univ Fed Sao Paulo, Ctr Res & Mol Diagnost Genet Dis, Dept Biophys, Sao Paulo, Brazil
[2] Univ Fed Sao Paulo, Dept Med, Div Nephrol, Sao Paulo, Brazil
[3] Univ Fed Sao Paulo, Dept Biophys, Sao Paulo, Brazil
基金
巴西圣保罗研究基金会;
关键词
COVID-19; SARS-CoV-2; ACE2; RAAS; Proteases; RENIN-ANGIOTENSIN SYSTEM; DIPEPTIDYL PEPTIDASE-IV; CATHEPSIN-L; PROLYL OLIGOPEPTIDASE; CYSTEINE CATHEPSINS; SARS CORONAVIRUS; RECEPTOR; INHIBITORS; INFLAMMATION; POLYMORPHISM;
D O I
10.1007/s00011-023-01775-3
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Objective and designCirculating enzymatic activity and RAAS regulation in severe cases of COVID-19 remains unclear, therefore we measured the serum activity of several proteases as potential targets to control the SARS-CoV-2 infection.Material or subjects152 patients with COVID-19-like symptoms were grouped according to the severity of symptoms (COVID-19 negative, mild, moderate and severe).MethodsSerum samples of COVID-19 patients and controls were subjected to biochemical analysis and enzymatic assays of ACE2, ACE, DPPIV, PREP and CAT L. One-way ANOVA and multivariate logistic regression analysis were used. Statistical significance was accepted at p < 0.05.ResultsWe detected a positive correlation among comorbidities, higher C-reactive protein (CRP) and D-dimer levels with disease severity. Enzymatic assays revealed an increase in serum ACE2 and CAT L activities in severe COVID-19 patients, while ACE, DPPIV and PREP activities were significantly reduced. Notably, analysis of ACE2/ACE activity ratio suggests a possible imbalance of ANG II/ANG(1-7) ratio, in a positive association with the disease severity.ConclusionOur findings reveal a correlation between proteases activity and the severity of COVID-19. These enzymes together contribute to the activation of pro-inflammatory pathways, trigger a systemic activation of inflammatory mediators, leading to a RAAS dysregulation and generating a significant damage in several organs, contributing to poor outcomes of severe cases.
引用
收藏
页码:1719 / 1731
页数:13
相关论文
共 50 条
[41]   ACE2 and COVID-19: using antihypertensive medications and pharmacogenetic considerations [J].
Snyder, Eric M. ;
Johnson, Bruce D. .
PHARMACOGENOMICS, 2020, 21 (10) :695-703
[42]   Role of SARS-CoV-2 and ACE2 variations in COVID-19 [J].
Antony, Priya ;
Vijayan, Ranjit .
BIOMEDICAL JOURNAL, 2021, 44 (03) :235-244
[43]   The Protective Potential Role of ACE2 against COVID-19 [J].
Golab, Fereshteh ;
Vahabzadeh, Gelareh ;
SadeghRoudbari, Leila ;
Shirazi, Arefeh ;
Shabani, Robabeh ;
Tanbakooei, Sara ;
Kooshesh, Lida .
ADVANCES IN VIROLOGY, 2023, 2023
[44]   Expression of ACE2, Soluble ACE2, Angiotensin I, Angiotensin II and Angiotensin-(1-7) Is Modulated in COVID-19 Patients [J].
Osman, Ikram Omar ;
Melenotte, Clea ;
Brouqui, Philippe ;
Million, Matthieu ;
Lagier, Jean-Christophe ;
Parola, Philippe ;
Stein, Andreas ;
La Scola, Bernard ;
Meddeb, Line ;
Mege, Jean-Louis ;
Raoult, Didier ;
Devaux, Christian A. .
FRONTIERS IN IMMUNOLOGY, 2021, 12
[45]   ACE2 as a potential therapeutic target for pandemic COVID-19 [J].
Chatterjee, Bhaswati ;
Thakur, Suman S. .
RSC ADVANCES, 2020, 10 (65) :39808-39813
[46]   Natural Products Modulating Angiotensin Converting Enzyme 2 (ACE2) as Potential COVID-19 Therapies [J].
Abubakar, Murtala Bello ;
Usman, Dawoud ;
El-Saber Batiha, Gaber ;
Cruz-Martins, Natalia ;
Malami, Ibrahim ;
Ibrahim, Kasimu Ghandi ;
Abubakar, Bilyaminu ;
Bello, Muhammad Bashir ;
Muhammad, Aliyu ;
Gan, Siew Hua ;
Dabai, Aliyu Ibrahim ;
Alblihed, M. ;
Ghosh, Arabinda ;
Badr, Reem H. ;
Thangadurai, Devarajan ;
Imam, Mustapha Umar .
FRONTIERS IN PHARMACOLOGY, 2021, 12
[47]   Regulated Intramembrane Proteolysis of ACE2: A Potential Mechanism Contributing to COVID-19 Pathogenesis? [J].
Gonzalez, Sandra M. ;
Siddik, Abu Bakar ;
Su, Ruey-Chyi .
FRONTIERS IN IMMUNOLOGY, 2021, 12
[48]   Variants in ACE2; potential influences on virus infection and COVID-19 severity [J].
Bakhshandeh, Behnaz ;
Sorboni, Shokufeh Ghasemian ;
Javanmard, Amir-Reza ;
Mottaghi, Seyed Saeed ;
Mehrabi, Mohammad-Reza ;
Sorouri, Farzaneh ;
Abbasi, Ardeshir ;
Jahanafrooz, Zohreh .
INFECTION GENETICS AND EVOLUTION, 2021, 90
[49]   Angiotensin-converting enzymes (ACE, ACE2) gene variants and COVID-19 outcome [J].
Gomez, Juan ;
Albaiceta, Guillermo M. ;
Garcia-Clemente, Marta ;
Lopez-Larrea, Carlos ;
Amado-Rodriguez, Laura ;
Lopez-Alonso, Ines ;
Hermida, Tamara ;
Enriquez, Ana I. ;
Herrero, Pablo ;
Melon, Santiago ;
Alvarez-Argueelles, Marta E. ;
Boga, Jose A. ;
Rojo-Alba, Susana ;
Cuesta-Llavona, Elias ;
Alvarez, Victoria ;
Lorca, Rebeca ;
Coto, Eliecer .
GENE, 2020, 762
[50]   Genotype variation of ACE and ACE2 genes affects the severity of COVID-19 patients [J].
Ingrid Faustine ;
Deli Marteka ;
Amarila Malik ;
Eko Supriyanto ;
Nadia F. Syafhan .
BMC Research Notes, 16